Jun 16, 2026Metabolic TherapeuticsGLP-1 vs. SGLT2: Which Cardiorenal Benefit Matters Most?GLP-1 receptor agonists and SGLT2 inhibitors can retain benefits together, but kidney, heart-failure, stroke, and MACE evidence differs.glp-1 receptor agonistssglt2 inhibitorscardiorenal outcomesmaceRead article →
Mar 21, 2026Metabolic DrugsGLP-1 Heart Benefits: Blood Pressure Matters, But So Does WeightGLP-1 drugs cut major cardiovascular events. Ambulatory monitoring suggests blood pressure gets more credit—but weight and direct effects still matter.glp-1 agonistssemaglutideblood pressurecardiovascular outcomesRead article →
Mar 1, 2026Cardiovascular HealthGLP-1s Cut Heart Failure Risk Only in ObesityGLP-1 drugs lower cardiovascular death broadly, but heart failure hospitalization benefit appears limited to obesity-driven disease.glp-1heart failureobesityhfpefRead article →